Upfront CAR T-Cell Therapy to Upgrade Response in Myeloma. Sergio Giralt, MD | #ASH2025

Idecabtagene vicleucel (ide-cel; Abecma) resulted in high rates of complete response (CR) and minimal residual disease (MRD) negativity in patients with multiple myeloma who experienced a suboptimal response to standard first-line therapy including autologous hematopoietic cell transplant (auto-HCT) and lenalidomide (Revlimid) maintenance, according to topline findings from the phase 2 BMT CTN 1902 trial (NCT05032820)